Provided by Tiger Trade Technology Pte. Ltd.

Cellectar Biosciences

2.52
-0.0700-2.70%
Post-market: 2.51-0.0100-0.40%16:12 EDT
Volume:23.17K
Turnover:59.02K
Market Cap:23.82M
PE:-1.14
High:2.59
Open:2.56
Low:2.50
Close:2.59
52wk High:6.52
52wk Low:2.20
Shares:9.45M
Float Shares:9.01M
Volume Ratio:0.58
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2100
EPS(LYR):-8.3544
ROE:-119.57%
ROA:-58.44%
PB:0.80
PE(LYR):-0.30

Loading ...

Cellectar BioSciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Oncology Platform, Iopofosine I-131 Program

Reuters
·
Aug 19

Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)

TIPRANKS
·
Aug 17

Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar

TIPRANKS
·
Aug 15

Stempoint Capital Lp Reports 9.9% Passive Stake in Cellectar Biosciences Inc as of June 30- SEC Filing

THOMSON REUTERS
·
Aug 15

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 14

Cellectar Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Cellectar Biosciences Q2 Net Income USD -6.9 Million

THOMSON REUTERS
·
Aug 13

Cellectar Biosciences - Initiates Site Activation for Phase 3 Iopfosine I 131 Study; Nda Submission Planned Mid-2027

THOMSON REUTERS
·
Aug 13

Cellectar Biosciences Q2 EPS USD -0.57

THOMSON REUTERS
·
Aug 13

Cellectar Biosciences - Reports Cash and Cash Equivalents of $34 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 13

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

THOMSON REUTERS
·
Aug 13

Cellectar BioSciences FY26 Q2 Net Loss Widens to About $12.6 Million; R&D Expense Rises 91% to About $4.56 Million vs FY25 Q2

Reuters
·
Aug 13

Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate

Benzinga Earnings
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

Cellectar Biosciences Inc Expected to Post a Loss of 48 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Cellectar BioSciences Schedules Quarterly Results Conference Call

Reuters
·
Jul 30

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

GlobeNewswire
·
Jul 30

Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia

Reuters
·
Jul 21

Cellectar Reports Phase 1 Study Publication Supports Iopofosine I-131 Potential in Relapsed Multiple Myeloma

Reuters
·
Jul 15

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

GlobeNewswire
·
Jul 15